Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Taxes: 2017-2024

Historic Change in Taxes for Ligand Pharmaceuticals (LGND) over the last 8 years, with Dec 2024 value amounting to -$2.3 million.

  • Ligand Pharmaceuticals' Change in Taxes fell 109.50% to -$864,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 179.69%. This contributed to the annual value of -$2.3 million for FY2024, which is 229.70% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Change in Taxes is -$2.3 million, which was down 229.70% from $1.8 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Change in Taxes high stood at $4.0 million for FY2021, and its period low was -$9.1 million during FY2020.
  • For the 3-year period, Ligand Pharmaceuticals' Change in Taxes averaged around -$702,667, with its median value being -$1.6 million (2022).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Change in Taxes soared by 212.79% in 2023, and later tumbled by 229.70% in 2024.
  • Ligand Pharmaceuticals' Change in Taxes (Yearly) stood at -$9.1 million in 2020, then spiked by 143.48% to $4.0 million in 2021, then plummeted by 139.71% to -$1.6 million in 2022, then surged by 212.79% to $1.8 million in 2023, then slumped by 229.70% to -$2.3 million in 2024.